Public disclosures

Zanganeh Mahkam

Company insiders · Co-Chief Executive Officer · Director · 10% owner · Summit Therapeutics Inc.

Advertisement
FollowLatest SEC filingSEC filer historyProfile details as reported on 2026-11-20.Following & alerts
Reported transaction lines
4
Buy lines
0
Sell lines
0

Filing activity by month

Original filing lines in up to 12 months with activity.

  • 2026-114

Frequently disclosed stocks

Disclosure history

More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSource
Zanganeh Mahkam

Co-Chief Executive Officer · Director · 10% owner · Summit Therapeutics Inc.

SMMT

Summit Therapeutics Inc.

Exercise or conversion
Filing details

SEC transaction code M

Stock Option (right to buy) · Derivative security · Direct ownership · Reported balance after transaction: 500000 · On November 20, 2026, the Reporting Person exercised an option to purchase 300,000 shares of the Issuer's common stock at an exercise price of $1.06 per share. · The option was granted on June 28, 2022, subject to certain performance criteria. On August 23, 2024, based on satisfaction of certain performance criteria, the option vested as to 260,000 shares. On April 29, 2025, the option was modified to require only the service-based vesting requirements to continue to be satisfied in order to become fully vested; the option vested as to 520,000 shares on April 29, 2025 and the remaining 520,000 will vest in three equal annual installments, with the first such installment having occurred on October 13, 2025.

2026-11-202026-11-20

300,000 shares/units

SEC 4
Zanganeh Mahkam

Co-Chief Executive Officer · Director · 10% owner · Summit Therapeutics Inc.

SMMT

Summit Therapeutics Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 831000 · On November 20, 2026, the Reporting Person exercised an option to purchase 300,000 shares of the Issuer's common stock at an exercise price of $1.06 per share.

2026-11-202026-11-20

300,000 shares/units

SEC 4
Zanganeh Mahkam

Co-Chief Executive Officer · Director · 10% owner · Summit Therapeutics Inc.

SMMT

Summit Therapeutics Inc.

Exercise or conversion
Filing details

SEC transaction code M

Stock Option (right to buy) · Derivative security · Direct ownership · Reported balance after transaction: 800000 · On November 16, 2026, the Reporting Person exercised an option to purchase 500,000 shares of the Issuer's common stock at an exercise price of $1.06 per share. · The option was granted on June 28, 2022, subject to certain performance criteria. On August 23, 2024, based on satisfaction of certain performance criteria, the option vested as to 260,000 shares. On April 29, 2025, the option was modified to require only the service-based vesting requirements to continue to be satisfied in order to become fully vested; the option vested as to 520,000 shares on April 29, 2025 and the remaining 520,000 will vest in three equal annual installments, with the first such installment having occurred on October 13, 2025.

2026-11-162026-11-16

500,000 shares/units

SEC 4
Zanganeh Mahkam

Co-Chief Executive Officer · Director · 10% owner · Summit Therapeutics Inc.

SMMT

Summit Therapeutics Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 531000 · On November 16, 2026, the Reporting Person exercised an option to purchase 500,000 shares of the Issuer's common stock at an exercise price of $1.06 per share.

2026-11-162026-11-16

500,000 shares/units

SEC 4

Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.

Advertisement